UNSPSC 51434964: Acetylsalicylic acid/ramipril/simvastatin

Acetylsalicylic acid/ramipril/simvastatin is a fixed-dose triple combination therapy of an antiplatelet (aspirin), statin (simvastatin) and ACE inhibitor (ramipril) used for secondary prevention of cardiovascular disease and treatment of hypertension.

UNSPSC 51434964 Acetylsalicylic acid/ramipril/simvastatin is a Commodity code that captures pharmaceutical combination products used in state and local healthcare delivery, particularly through emergency medical services, public health clinics, and forensic laboratory operations. Recent state and local opportunities show mixed relevance to this specific code: solicitations under the code's nominal scope are sparse, while adjacent pharmaceutical and medical supply procurements dominate activity. The Seminole County, Florida IFB for naloxone and safe drug deactivation systems (due July 26, 2023) and the City of Tucson Fire Department RFP for BLS/ALS pharmaceuticals and supplies (due June 24, 2026) represent the closest activity, though neither directly addresses acetylsalicylic acid/ramipril/simvastatin formulations. Issuing bodies include county governments (Seminole County, Pinellas County), cities (Tucson), and specialized public agencies such as fire departments and forensic laboratories. The geographic spread spans Florida, Arizona, and scattered state-level cooperative purchasing vehicles, with Florida showing the highest recent posting volume through Seminole County and Pinellas County procurement activity.

The Tucson Fire Department solicitation, the most substantive recent opportunity in the pharmaceutical space, seeks comprehensive BLS and ALS pharmaceuticals and supplies on an RFP basis with federal compliance obligations (ARPA, HUD, FTA grants, prevailing wage, Davis-Bacon, DBE participation, Section 3 labor requirements). The procurement specifies 251 line items including medications, diagnostic equipment, and IV administration supplies with estimated annual usage volumes ranging from 1 to 120,000 units per item, demanding Arizona State Board of Pharmacy licensure as a wholesaler and FDA/DEA/Drug Supply Chain Security Act compliance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) offers broader state and local reach across participating jurisdictions in multiple states, requiring cGMP and DSCSA certification, pricing submission through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), and compliance with 3 percent administrative fees. This code shows active procurement in emergency medical services and clinical settings but does not report standing demand specifically for acetylsalicylic acid/ramipril/simvastatin three-drug combinations as a distinct line item across recent solicitations.